The United Kingdom and the United States have agreed to a important commercial pact that will preserve no tariffs on British pharmaceutical products entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has pledged to increase funding on drugs through the NHS. This commitment secures that tariffs on these key exports will stay at zero for a duration of 36 months.
This deal comes after recent warnings to hike import taxes on patented drug products, with potential rates floated as high as double the cost.
"This arrangement between the Britain strengthens the international landscape for innovative medicines and establishes long-overdue equity to U.S.–U.K. pharmaceutical trade," a release said.
Economic Significance
Drugs are one of the the United Kingdom's most significant goods shipped to the United States, which is easily the biggest buyer for leading British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to last September, the UK shipped medicines valued at £11.1bn to the US. This value made up a significant portion of British export trade in that period.
"This guarantee secures employment, stimulates investment and facilitates the UK to become a international leader for biotech and pharma," the Business and Trade Secretary stated.
Detailed UK Commitments
The pact includes several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it considers new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a target to double total NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount manufacturers must return to the NHS to control costs will be limited at fifteen percent. Last year, rebates were more than 20%.
Recent Tensions
The pact follows a ongoing tension between the pharmaceutical industry and the British authorities over medicine costs and regulatory access.
These tensions were intensified by arguments that American customers were charged a premium for the same drugs than people in the Britain and the EU.
Over the last 18 months, several major drug company projects in the UK have been paused or scrapped, while major funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the past decade.
